Cheratoacantoma
Revisione paritaria di Dr Krishna Vakharia, MRCGPUltimo aggiornamento di Dr Colin Tidy, MRCGPUltimo aggiornamento 23 Nov 2022
Rispetta le linee guida editoriali
- ScaricaScarica
- Condividi
- Language
- Discussione
- Versione audio
Professionisti Medici
Gli articoli di riferimento professionale sono progettati per essere utilizzati dai professionisti della salute. Sono scritti da medici del Regno Unito e basati su prove di ricerca, linee guida del Regno Unito e europee. Potresti trovare uno dei nostri articoli sulla salute più utile.
In questo articolo:
Continua a leggere sotto
What are keratoacanthomas?
Keratoacanthomas (KAs) are very rapidly growing squamo-proliferative lesions that look like well-differentiated squamous cell carcinomas (SCCs) pathologically. Keratoacanthomas are characterised by rapid growth over a few weeks to months, followed by spontaneous resolution over 4-6 months in most cases.
Keratoacanthomas are benign epidermal growths and not a malignant variant of SCC.1
How common are keratoacanthomas? (Epidemiology)
Torna ai contenutiIncidence is estimated at 1 in 1,000.
Peak incidence occurs in those aged over 60 years. It is rare in young adults.
It is uncommon in darker-skinned patients.
Males are twice as often affected as females.
Epidemiological data are similar to SCC and Bowen's disease in terms of age, sex and the site of lesions.
Fattori di rischio
Sunlight and chemical carcinogens have been implicated.
Trauma, genetic factors and immunocompromised status have also been associated.
Industrial workers exposed to pitch and tar have a higher incidence of both keratoacanthoma and SCC.
Continua a leggere sotto
Keratoacanthoma symptoms
Torna ai contenutiTypically, rapid growth over a few weeks to months, followed by a slow spontaneous resolution over 4-6 months (but may take up to one year).
Most occur on sun-exposed areas - eg, the face, neck, and dorsum of hands and forearms.
They are usually solitary and begin as firm, round, skin-coloured or reddish papules that rapidly progress to dome-shaped nodules with a smooth shiny surface. A central crater of ulceration may develop, or a keratin plug that may project like a horn.
They leave a residual scar if not excised.
A recent large systematic review has shown that none of the cases of keratoacanthoma from 113 published articles resulted in death or distant metastases. This was compared with 429 cases of SCC of the skin, with 61 cases of metastases and 24 deaths as a direct result of SCC. The authors clearly state that the biological behaviour of the keratoacanthomas and SCCs is distinct and evident.1
Generalised eruptive keratoacanthoma (GEKA) of Grzybowski is a sporadically occurring, extremely rare variant of KA characterised clinically by severely pruritic, generalised eruption of numerous small follicular papules, often with a central keratotic plug, and histologically by typical features of solitary keratoacanthoma.2 .
Cheratoacantoma

© Jmarchn, CC BY-SA 3.0, via Wikimedia Commons
Diagnosi differenziale3 4
Torna ai contenutiContinua a leggere sotto
Indagini
Torna ai contenutiShave biopsy of keratoacanthoma is indistinguishable from invasive SCC. Therefore, excisional or deep incisional biopsy is required.
A recent study has demonstrated that there is a large regional variation in the diagnosis of keratoacanthoma and SCCs in Great Britain and Ireland.5
This is because microscopic differentiation between these two entities is often problematic, and sometimes impossible.6
Keratoacanthoma treatment and management
Torna ai contenutiAs they are hard to distinguish from SCCs, patients with suspected keratoacanthomas should be referred under the two-week waiting system. However, the patient can be reassured that they will not cause harm.
Complete excision is the treatment of choice for all skin lesions thought to be keratoacanthoma.
Medical treatment is reserved for when surgical intervention is not possible - eg, multiple lesions not amenable to surgery because of size or location.
Treatments that have produced some success include systemic retinoids (eg, isotretinoin), intralesional methotrexate, 5-fluorouracil, bleomycin and steroids, and topical imiquimod, and 5-fluorouracil.7 8
Prognosi
Torna ai contenutiPrognosis is excellent following excisional surgery. Recurrence after surgical resection is rare.9
Without surgery, prognosis is usually good; however, there is a major controversy over the natural behaviour of KA. keratoacanthomas have been described as benign lesions, but also as variants of SCC.6
Prevention of keratoacanthomas
Torna ai contenutiPatient education in sun-protection is important.
Ulteriori letture e riferimenti
- Cheratoacantoma; DermNet NZ
- Zito PM, Scharf R; Keratoacanthoma. StatPearls, Aug 2022.
- Cheratoacantoma; Società di Dermatologia delle Cure Primarie.
- Savage JA, Maize JC Sr; Keratoacanthoma clinical behavior: a systematic review. Am J Dermatopathol. 2014 May;36(5):422-9. doi: 10.1097/DAD.0000000000000031.
- Nofal A, Assaf M, Nofal E, et al; Generalized eruptive keratoacanthoma: proposed diagnostic criteria and therapeutic evaluation. J Eur Acad Dermatol Venereol. 2014 Apr;28(4):397-404. doi: 10.1111/jdv.12226. Epub 2013 Aug 6.
- Stefaniak AA, Chlebicka I, Krajewski P, et al; Do Not Judge a Book by its Cover: Masquerading as Keratoacanthoma. Acta Derm Venereol. 2020 Mar 12;100(6):adv00074. doi: 10.2340/00015555-3423.
- Riahi RR, Cohen PR; Malignancies with skin lesions mimicking keratoacanthoma. Dermatol Online J. 2013 Nov 15;19(11):20397.
- Carr RA, Houghton JP; Histopathologists' approach to keratoacanthoma: a multisite survey of regional variation in Great Britain and Ireland. J Clin Pathol. 2014 Apr 24. doi: 10.1136/jclinpath-2014-202255.
- Lammoglia-Ordiales L, Toussaint-Caire S, Contreras-Barrera M, et al; Assessment of syndecan-1 (CD138) and Ki-67 expression for differentiating keratoacanthoma and squamous cell carcinoma. J Drugs Dermatol. 2013 Mar;12(3):e53-8.
- Aubut N, Alain J, Claveau J; Intralesional methotrexate treatment for keratoacanthoma tumors: a retrospective case series. J Cutan Med Surg. 2012 May-Jun;16(3):212-7.
- Plachouri KM, Mulita F, Bousis D, et al; Successful treatment of a keratoacanthoma in a young patient with the application of topical 5% imiquimod cream. Clin Case Rep. 2021 Nov 6;9(11):e04920. doi: 10.1002/ccr3.4920. eCollection 2021 Nov.
- Liu XG, Liu XG, Wang CJ, et al; Lower lip recurrent keratoacanthoma: A case report. World J Clin Cases. 2022 Jul 16;10(20):6960-6965. doi: 10.12998/wjcc.v10.i20.6960.
Continua a leggere sotto
Storia dell'articolo
Le informazioni su questa pagina sono scritte e revisionate da clinici qualificati.
Prossima revisione prevista: 22 Nov 2027
23 Nov 2022 | Ultima versione

Chiedi, condividi, connettiti.
Esplora le discussioni, fai domande e condividi esperienze su centinaia di argomenti di salute.

Non ti senti bene?
Valuta i tuoi sintomi online gratuitamente